Tigecycline
- Generic Name
- Tigecycline
- Brand Names
- Tygacil, Tigecycline Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39N5O8
- CAS Number
- 220620-09-7
- Unique Ingredient Identifier
- 70JE2N95KR
- Background
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
- Indication
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates only), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, ...
- Associated Conditions
- Bacterial Infections, Community Acquired Pneumonia (CAP), Complicated Intra-Abdominal Infections (cIAIs), Complicated Skin and Skin Structure Infection
- Associated Therapies
- -
Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms
- Conditions
- First Posted Date
- 2004-03-23
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 115
- Registration Number
- NCT00079989
Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Conditions
- First Posted Date
- 2004-03-22
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00079976
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
- Conditions
- First Posted Date
- 2004-03-19
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 430
- Registration Number
- NCT00079885
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.